Steady-state pharmacokinetic interactions of Darunavir/Ritonavir with lipid-lowering agent rosuvastatin

Journal of Clinical Pharmacology

Volumn 52, Issue 6, 2012, Pages 922-931

  Samineni, Divya ^a   Desai, Pankaj B ^a   Sallans, Larry ^a,c   Fichtenbaum, Carl J ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b College of Medicine ^*  (United States)

^c Rieveschl Laboratories for Mass Spectrometry   (United States)

Author keywords

darunavir; drug interactions; pharmacokinetics; protease inhibitors; rosuvastatin; statins

Indexed keywords

DARUNAVIR; DARUNAVIR PLUS RITONAVIR; LIPID; RITONAVIR; ROSUVASTATIN; TRIACYLGLYCEROL;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; MUSCLE WEAKNESS; PHASE 1 CLINICAL TRIAL; RESPIRATORY TRACT DISEASE; SINUS CONGESTION; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; CHOLESTEROL; CHOLESTEROL, HDL; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HALF-LIFE; HIV PROTEASE INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PYRIMIDINES; RITONAVIR; SULFONAMIDES; TIME FACTORS; TRIGLYCERIDES; YOUNG ADULT;

EID: 84861830855     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011407494     Document Type: Article

References (30)

1. Tenore SB, Ferreira PR. The place of protease inhibitors in antiretroviral treatment. Braz J Infect Dis. 2009 ; 13 (5). 371-374
2. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2001 ; 2 (2). 105-113
3. Martinez E, Domingo P, Galindo MJ, et al. Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis. 2004 ; 38 (7). 1017-1023
4. Gathe J, da Silva BA, Loutfy M, et al. Study M05-730 primary efficacy results at week 48: phase 3, randomized, open-label study of lopinavir/ritonavir (LPV/r) tablets once daily (qd) versus twice daily (bid), co-administered with tenofovir DF (TDF) + emtricitabine (FTC) in antiretroviral-naïve (ARV) HIV-1-infected subjects. Poster presented at: 15th Conference on Retroviruses and Opportunistic Infections ; Boston, MA ;..
5. Manfredi R, Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J Infect. 2001 ; 42 (3). 181-188
6. Sekar V, Kestens D, Spinosa-Guzman S, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol. 2007 ; 47 (4). 479-484
7. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs. 2003 ; 63 (8). 769-802
8. Le TC, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin Pharmacokinet. 2005 ; 44 (10). 1035-1050
9. Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS. 2009 ; 23 (13). 1679-1688
10. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003 ; 37 (5). 613-627
11. Dixit V, Hariparsad N, Li F, Desai P, Thummel KE, Unadkat JD. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 ; 35 (10). 1853-1859
12. Bachmeier CJ, Spitzenberger TJ, Elmquist WF, Miller DW. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm Res. 2005 ; 22 (8). 1259-1268
13. Carr RA, Andre AK, Bertz RJ. Concomitant administration of ABT-378/ritonavir results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin. Poster presented at: 40th Conference on Antimicrobial Agents and Chemotherapy ; Toronto, Ontario, Canada ;..
14. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002 ; 16 (4). 569-577
15. Kiser JJ, Gerber JG, Predhomme JA, Wolfe P, Flynn DM, Hoody DW. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2008 ; 47 (5). 570-578
16. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther. 2002 ; 72 (6). 685-691
17. Sekar VJ, Spinosa-Guzman S, Marien K, et al. Pharmacokinetic drug-drug interaction between the new HIV protease inhibitor darunavir (TMC114) and the lipid-lowering agent pravastatin. Poster presented at: Eighth International Workshop on Clinical Pharmacology of HIV Therapy ; Budapest, Hungary ;..
18. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92 (2). 152-160
19. Trivedi RK, Kallem RR, Mullangi R, Srinivas NR. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. J Pharm Biomed Anal. 2005 ; 39 (3-4). 661-669
20. Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos. 2008 ; 36 (10). 2014-2023
21. Ho RH, Tirona RG, Leake BF, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 ; 130 (6). 1793-1806
22. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther. 2004 ; 76 (2). 167-177
23. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther. 2004 ; 75 (1). 101-109
24. Jemnitz K, Veres Z, Tugyi R, Vereczkey L. Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. Toxicol In Vitro. 2010 ; 24 (2). 605-610
25. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol. 2002 ; 58 (8). 527-531
26. Annaert P, Ye ZW, Stieger B, Augustijns P. Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1. Xenobiotica. 2010 ; 40 (3). 163-176
27. Tirona RG, Leake BF, Wolkoff AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 ; 304 (1). 223-228
28. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005 ; 7 (1). E118 - E133
29. Takano M, Yumoto R, Murakami T. Expression and function of efflux drug transporters in the intestine. Pharmacol Ther. 2006 ; 109 (1-2). 137-161
30. Bierman WF, Scheffer GL, Schoonderwoerd A, et al. Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother. 2010 ; 65 (8). 1672-1680